ProKidney Corp. (PROK)
NASDAQ: PROK · Real-Time Price · USD
0.9902
+0.0801 (8.80%)
At close: Apr 24, 2025, 4:00 PM
0.9921
+0.0019 (0.19%)
After-hours: Apr 24, 2025, 7:12 PM EDT

Company Description

ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States.

Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes.

The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel.

ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.

ProKidney Corp.
ProKidney logo
Country United States
Founded 2015
Industry Biotechnology
Sector Healthcare
Employees 204
CEO Bruce Culleton

Contact Details

Address:
2000 Frontis Plaza Blvd., Suite 250
Winston-Salem, North Carolina 27103
United States
Phone 336 999 7028
Website prokidney.com

Stock Details

Ticker Symbol PROK
Exchange NASDAQ
Share Class Class A Shares
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001850270
ISIN Number KYG7S53R1049
Employer ID 98-1586514
SIC Code 2836

Key Executives

Name Position
Dr. Bruce Culleton M.D. Chief Executive Officer and Director
Dr. Ulrich Ernst Ph.D. Executive Vice President of Science and Technology
Todd C. Girolamo Esq., J.D., M.B.A. Chief Legal Officer and Secretary
James Coulston CPA Chief Financial Officer
Anu Biswas Senior Vice President of Manufacturing and Operations
Richard Williams Chief Information Officer
Carla Poulson Chief People Officer
Dr. Joseph M. Stavas M.D., M.P.H. SVice President of Clinical Affairs
Dr. Darin J. Weber Ph.D. Chief Reg. Off, SVice President and Head of Global Reg. Affairs, Quality Mgmt, Biometrics and Market Access
Nikhil L. Pereira-Kamath Chief Business Officer

Latest SEC Filings

Date Type Title
Mar 31, 2025 S-4 Filing
Mar 20, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 17, 2025 10-K Annual Report
Mar 17, 2025 8-K Current Report
Feb 6, 2025 SCHEDULE 13D/A Filing
Jan 21, 2025 8-K Current Report
Nov 22, 2024 8-K Current Report
Nov 12, 2024 10-Q Quarterly Report
Nov 12, 2024 8-K Current Report
Nov 8, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals